

Naushin Hooda, R.Ph., Pharm.D., M.P.H, G.Dip, H.Bsc., B.Sc.

SENIOR EPIDEMIOLOGIST I

CONTACT INFORMATION

EpidStrategies, A BlueRidge Life Sciences Company
10520 Yonge Street, Unit 35B
Suite #208
Richmond Hill, Ontario
Canada L4C 3C7
Phone (240) 552-9474, x. 8017
nhooda@epidstrategies.com

PROFESSIONAL PROFILE

Dr. Naushin Hooda is a Doctor of Pharmacy, based in Toronto, Ontario. She has 5 years of professional experience, during and following her doctoral work, gaining broad expertise in the medical treatment and pharmaceutical arena within the Canadian clinical practice and pharmaceutical regulatory framework. Dr. Hooda's expertise is not limited to Canada, however. Most recently, she worked on medical strategic planning for a major pharmaceutical company's respiratory vaccine product in development for the U.S. market. During this process, she helped identify opportunities for scientific growth, conducted data needs assessment with engagement of key stakeholders, and executed initiatives such as real-world evidence generation, publication planning, and development of continuing education for medical providers.

Dr. Hooda's experience includes work in health and pharmacy business development, direct patient care services in multiple health-care facilities, and a position as a post-doctoral medical affairs resident for the Canadian arm of a pharmaceutical developer/manufacturer. During her doctoral work, she gained experience collaborating with organizations outside of academia, and she was awarded multiple scholarships and awards for academic excellence, research, leadership, community initiatives, and overall contributions to pharmacy.

EDUCATION AND DEGREES EARNED

- 2023 Master of Public Health
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 2023 Graduate Diploma in Pharmacoepidemiology
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 2019 Doctor of Pharmacy, (Dean's List)
University of Waterloo, School of Pharmacy, Waterloo, Ontario
- 2019 Bachelor of Science in Biomedical Sciences
University of Waterloo, Faculty of Science, Waterloo, Ontario
- 2016 Bachelor of Science in Human Biology (Specialist) and Psychology (Minor), with Distinction
University of Toronto, Faculty of Arts and Science, Toronto, Ontario

CERTIFICATIONS AND TRAINING

- 2020–2021 Drug Safety and Effectiveness Cross-Disciplinary Training Program, Canadian Institute of Health Research
- 2019–2020 Industrial Pharmacy Residency Program (IPRP), Faculty of Pharmacy, University of Toronto
- 2019 Canadian Pharma Market Regulations, Pharmaceutical Advertising Advisory Board
- 2018 Health Coaching Cardiovascular Program, Green Shield Canada
- 2015 Researchers Conducting Retrospective Review of Health Records, Hamilton Health Sciences

PROFESSIONAL AFFILIATIONS

- Ontario College of Pharmacists (OCP) — Registered Pharmacist
- Ontario Pharmacists' Association (OPA) — Member & Selected Feature (*International Women's Day & Pharmacist Awareness Month*)
- Canadian Association of Pharmacy in Oncology (CAPHo) — Awards Committee Member, Chapter Founder & Past Chapter President
- Science-to-Business Network (S2BN) — Chapter Founder & Past Chapter Director
- Canadian Society of Hospital Pharmacists (CSHP) — Member
- Canadian Agency for Drugs and Technologies Assessment (CADTH) — 2020 Conference Working Group
- Medical Affairs Professional Society — Member
- Women in the Enterprise of Science & Technology — Member

RECOGNITIONS/AWARDS

- 2019 President Recognition Award, University of Waterloo
- 2019 Leadership Award, Society of Pharmacy Students
- 2019 Student of Distinction Award, Ontario Pharmacists Association

- 2019 GSK/CSPS National Undergraduate Student Research Program Award, Canadian Society of Pharmaceutical Sciences
- 2018 Atkinson Citizenship Award, University of Waterloo Faculty of Science
- 2018 Centennial Leadership Award, Canadian Pharmacists' Association
- 2018 Guy Genest Passion for Pharmacy Award, Canadian Association for Pharmacy Students and Interns
- 2017 Student Member Award, Canadian Association of Pharmacy in Oncology
- 2015 Letter Award, University of Toronto

SELECTED PROFESSIONAL EXPERIENCE

Pharmaceutical Industry

Contributed to medical strategic planning for a respiratory vaccine pipeline product in the US market through the identification of key opportunities for scientific growth, data needs assessment with internal and external stakeholder engagement, and execution of joint initiatives, including externally sponsored research, real-world evidence generation, publication planning, and development of continuing medical education for health-care professionals.

Collaborated cross-functionally to objectively communicate balanced scientific and medical information on emerging data, including the development of presentations and information materials

Led the digital transformation of the external stakeholder engagement medium to incorporate platforms such as Within3, to facilitate operations during COVID-19.

Developed research protocols and manuscripts for publication through partnership with external collaborators and internal groups, including pharmacovigilance, health economics and outcomes research, vaccine epidemiology, and mathematical modeling, leading to the development and execution of protocols for three studies, including implementation of the company's first paperless survey utilizing electronic data capture tools.

Received corporate recognition for contributions to the global branding and contributions to the company's leadership program, a 3-year program for dual doctorate/MBA students.

Led the development of a vaccine-related business case study that was submitted to the Wharton Business School and selected for use in a first-year MBA course.

Clinical Pharmacy

Developed expertise in oncology, emergency, long-term care, and critical care settings

Conceptualized and launched a novel emergency room triage workflow in a rural hospital that incorporated a student pharmacist into the roles of medication assessment on triage, preliminary patient physical assessment, and post-diagnosis therapy selection, resulting in shorter wait times and enhanced satisfaction expressed by both patients and physicians.

Proposed innovative strategies, order sets, and protocols to meet hospital accreditation standards in accordance with relevant governing bodies, while minimizing drug waste and costs, and upholding patient safety standards.

Served as liaison with Cancer Care Ontario to implement a community-wide colorectal cancer screening plan for a rural community, including the design of a media/outreach campaign and patient communication tool, to ease the provincial transition to the fecal immunochemical test (FIT), addressing the unique systematic challenges and barriers of rural communities.

Contributed pharmaceutical expertise to the development of a computerized algorithm designed to screen, identify, and manage high-risk patients being treated with opioids, using electronic medical record software.

Led the national launch of a branded harm reduction and opioid crisis management support center for a large Canadian pharmacy retail chain for >1000 stores, including the development of opioid replacement therapy programs for pharmacy use in six provinces.

MANUSCRIPTS

Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V, ... Suh M, Reichert H, Mezzi K, Fryzek J, et al. 2024. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. *Eur J Cancer* 202(May):113975; doi: [10.1016/j.ejca.2024.113975](https://doi.org/10.1016/j.ejca.2024.113975).

Mitchell M, Suh M, Hooda N, Bylsma LC, Cohen S. 2024. The effect of bovine dairy products and their components on the incidence and natural history of infection: A systematic literature review. *Nutr J* 23(1):26; doi: [10.1186/s12937-024-00923-7](https://doi.org/10.1186/s12937-024-00923-7).

Suh M, Mitchell M, Hooda N, Bylsma LC, Cohen SS. 2024. The effects of dairy consumption on vaccine immune response and immunoglobulins: A systematic literature review. *Int J Nutr* 8(1):1–25; doi: [10.14302/issn.2379-7835.ijn-24-4938](https://doi.org/10.14302/issn.2379-7835.ijn-24-4938).

Mowva N, Reichert H, Hooda N, Bylsma LC, Mitchell M, Cohen SS. 2023. Dietary eating patterns, dairy consumption, and anxiety: A systematic literature review. *PLoS One* 18(12):e0295975; doi: [10.1371/journal.pone.0295975](https://doi.org/10.1371/journal.pone.0295975). PMID: 38153944.

Bylsma LC, Pundole X, Ju C-H, Hooda N, Mowva N, Elkhoully E, Bebb G, Fryzek J, et al. 2023. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. *Target Oncol* 18(6):821-835; doi: [10.1007/s11523-023-01008-x](https://doi.org/10.1007/s11523-023-01008-x).

Broome CM, Hooda N, Su J, Jiang X, Nicholson G, Frankenfeld CL, Iglesias-Rodriguez M, Fryzek J, Patel Parija. 2022. Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States. *PLoS One* 17(12):e0276617; doi: [10.1371/journal.pone.0276617](https://doi.org/10.1371/journal.pone.0276617).

Anneberg M, Svane HML, Fryzek J, Nicholson G, White JB, Edris B, Smith LM, Hooda N, Petersen MM, Baad-Hansen T, Keller JØ, Jørgensen PH, Pedersen AB. 2022. The epidemiology of desmoid tumors in Denmark. *Cancer Epidemiol* 77(Apr):102114; doi: [10.1016/j.canep.2022.102114](https://doi.org/10.1016/j.canep.2022.102114).

Elbeddini A, Tayefehchamani Y, Davey M, Gallinger J, Hooda N, Aly A, Erickson D, Lee S. 2021. Fournier's gangrene with dapagliflozin in a rural hospital: A case report. *BMJ Case Rep* 14(2):e237784; doi: [10.1136/bcr-2020-237784](https://doi.org/10.1136/bcr-2020-237784).

Vágó EK, Nicholson G, Horváth-Puhó E, Hooda N, Fryzek JP, Su J. 2021. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. *Curr Med Res Opin* 37(10):1829-1835; doi: [10.1080/03007995.2021.1960494](https://doi.org/10.1080/03007995.2021.1960494).

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. *Am J Case Rep* 21(Jun 28):e924058; doi: [10.12659/AJCR.924058](https://doi.org/10.12659/AJCR.924058).

Elbeddini A, Hooda N, Yang L. 2020. Role of Canadian pharmacists in managing drug shortage concerns amid the COVID-19 pandemic. *Canadian Pharm J* 153(4):198-203; doi: [10.1177/1715163520929387](https://doi.org/10.1177/1715163520929387).

Hooda N, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. *J Oncol Pharm Prac* (abstract 22); doi: [10.1177/1078155219834495](https://doi.org/10.1177/1078155219834495).

ABSTRACTS AND PRESENTATIONS

Nordyke RJ, Jensen I, **Hooda N**, Miller B. Rising levels of innovation in expedited designations among FDA-approved drugs: 2012-2024. Poster Session 2/No. HPR63, ISPOR 2026, Philadelphia, PA, May 18, 2026.

Desai NR, Fermann G, Pollack C, Venkatesh A, **Hooda N**, Jiang X, Sacks N, Holtz A, et al. Emergency department visits for PSVT: An analysis of the HCUP Nationwide Emergency Department Sample. Abstract 391, American College of Emergency Physicians (ACEP) Research Forum, Salt Lake City, UT. *Ann Emerg Med* 86(3S1):S169; doi: 10.1016/j.annemergmed.2025.06.409, September 2025.

Desai NR, Piccini JP, Sacks NC, Reichert H, **Hooda N**, Jiang X, Blood AJ, Holz A, et al. Emergency department visits and inpatient admissions for atrial fibrillation in the United States (US): 2015-2019. Abstract I10, Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Houston, TX. *J Manag Care Spec Pharm* 31(3-a Suppl):S74; doi: 10.18553/jmcp.2025.31.3-a.s1, March 31-April 3, 2025.

Yoshino T, **Hooda N**, Younan D, Shitara K, Heinemann V, ... Suh M, Reichert H, ... Fryzek J, et al. 127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness. *Ann Oncol* 34(Suppl 4):S1519 [abstract]; doi: 10.1016/j.annonc.2023.10.262, 2023.

Pundole X, Ju C-H, Bylsma LC, **Hooda N**, Mowva N, Elkhoully E, Bebb DG, Fryzek J, et al. Prevalence of delta-like ligand 3 expression in small cell lung cancer. *J Clinical Oncol* 41:16_suppl e20618, 2023.

Hooda N, Svane HML, Fryzek J, Nicholson G, White JB, Edris B, Smith LM, Petersen MM, Baad-Hansen T, Keller JØ, Jørgensen PH, Pedersen AB. 2021. The epidemiology of desmoid tumors in Denmark. Poster presented at the Connective Tissue Oncology Society Annual Meeting, November 2021.

Vágó EK, Nicholson G, Horváth-Puhó E, **Hooda N**, Fryzek J, Su J. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. E-poster presentation to European Hematology Association Virtual Congress, June 2021.

Fergie J, Gonzales T, Suh M, Jiang X, Fryzek JP, **Hooda N**, Howard A, Bloomfield A. Higher-risk congenital heart disease (CHD) among children aged ≤ 24 months with respiratory syncytial virus hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH). 37th Annual Children's National Symposium: ECMO and the Advanced Therapies for Cardiovascular and Respiratory Failure, Feb 2021.

Fergie J, Gonzales T, Suh M, Jiang X, Fryzek J, **Hooda N**, Howard A, Bloomfield A. Higher-risk congenital heart disease (CHD) among children aged ≤ 24 months with respiratory syncytial virus hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH) at RSV season before and after the 2014 American Academy of Pediatrics (AAP) guidance. California Association of Neonatologists' 27th Annual Cool Topics in Neonatology Conference, March 2021.

Hooda N, McFarlane T, Pasetka M, DeAngelis C. Chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer (CRC) patients undergoing FOLFOX Chemotherapy: A retrospective chart review comparing two Ontario hospitals. Abstract accepted for publication in *J Pharmacy Pharmaceut Sci*. Poster presented at the Canadian Society for Pharmaceutical Sciences Annual Conference, Vancouver, BC, May 2019.

Hooda N, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. Poster presented at the Canadian Association for Pharmacy in Oncology Annual Conference, Halifax, NS, April 2019.

Hooda N, McFarlane T, Pasetka M, DeAngelis C. 2018. Investigating guideline-consistent anti-emetic prescribing practices at the Odette Cancer Centre (OCC). Poster for oral presentation seminar, "Meet the Future Leaders in Research," Ontario Pharmacist Conference, Huntsville, ON, June 2018.

PROTOCOL REGISTRATIONS

Rehn M, Chia V, Younan D, **Hooda N**, Fryzek J, Suh M, Mezzi K, Soeda J. 2024. An updated systematic literature review of safety and efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus Bevacizumab in adult patients with RAS wild-type left-sided metastatic colorectal cancer. PROSPERO 2024:CRD42022338784. Available from: <https://www.crd.york.ac.uk/PROSPERO/view/CRD42022338784>.

Bylsma L, Fryzek J, Mowa N, Frankenfeld C, **Hooda N**, Pundole X, et al. 2022. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. PROSPERO 2022 CRD42022351119. Available from: <https://www.crd.york.ac.uk/PROSPERO/view/CRD42022351119>.

Mitchell M, Cohen S, Mowa N, Bylsma L, **Hooda N**. 2022. Systematic review of the potential association dietary eating patterns (specifically *including* whole dairy products) and anxiety in humans. PROSPERO 2022 CRD42022333785. Available from: <https://www.crd.york.ac.uk/PROSPERO/view/CRD42022333785>.